Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Carlsson

Showing results (31-40 of 59) with videos related to

Pageof 6
Sort By:
Current Medical Research and Opinion|March 25, 2011
Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladderJacques Corcos, Javier C Angulo, Alan D Garely, et al.
Current Medical Research and Opinion|March 2, 2011
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptomsHarriette Scarpero, Peter K Sand, Con J Kelleher, et al.
BJU International|May 31, 2008
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom ScoreSteven A Kaplan, Claus G Roehrborn, Michael Chancellor, et al.
Chest|September 25, 2008
Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafilClaire Gilbert, Martin C J Brown, Joseph C Cappelleri, et al.
Drugs & Aging|January 27, 2012
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studiesPeter K Sand, John Heesakkers, Stephen R Kraus, et al.
Contemporary Clinical Trials|October 1, 2016
Development of a predictive model for urgency urinary incontinenceAmanda Darekar, Martin Carlsson, Sheila Quinn, et al.
Upsala Journal of Medical Sciences|November 11, 2008
Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acidsMarie Ohman, Torbjörn Akerfeldt, Ingela Nilsson, et al.
International Urogynecology Journal|April 6, 2017
Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladderAlexandra I Barsdorf, Martin Carlsson, Andrew G Bushmakin, et al.
JAMA|November 16, 2006
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trialSteven A Kaplan, Claus G Roehrborn, Eric S Rovner, et al.
Cardiology and Therapy|July 9, 2025
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOSJonas Wixner, Angela Dispenzieri, Leslie Amass, et al.
Pageof 6

Showing results (31-40 of 59) with videos related to

Sort By:
Pageof 6
Current Medical Research and Opinion|March 25, 2011
Effect of fesoterodine 4 mg on bladder diary and patient-reported outcomes during the first week of treatment in subjects with overactive bladderJacques Corcos, Javier C Angulo, Alan D Garely, et al.
Current Medical Research and Opinion|March 2, 2011
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptomsHarriette Scarpero, Peter K Sand, Con J Kelleher, et al.
BJU International|May 31, 2008
Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom ScoreSteven A Kaplan, Claus G Roehrborn, Michael Chancellor, et al.
Chest|September 25, 2008
Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafilClaire Gilbert, Martin C J Brown, Joseph C Cappelleri, et al.
Drugs & Aging|January 27, 2012
Long-term safety, tolerability and efficacy of fesoterodine in subjects with overactive bladder symptoms stratified by age: pooled analysis of two open-label extension studiesPeter K Sand, John Heesakkers, Stephen R Kraus, et al.
Contemporary Clinical Trials|October 1, 2016
Development of a predictive model for urgency urinary incontinenceAmanda Darekar, Martin Carlsson, Sheila Quinn, et al.
Upsala Journal of Medical Sciences|November 11, 2008
Biochemical effects of consumption of eggs containing omega-3 polyunsaturated fatty acidsMarie Ohman, Torbjörn Akerfeldt, Ingela Nilsson, et al.
International Urogynecology Journal|April 6, 2017
Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladderAlexandra I Barsdorf, Martin Carlsson, Andrew G Bushmakin, et al.
JAMA|November 16, 2006
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trialSteven A Kaplan, Claus G Roehrborn, Eric S Rovner, et al.
Cardiology and Therapy|July 9, 2025
Survival in a Contemporary, Real-World Cohort of Patients with Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis: An Analysis from THAOSJonas Wixner, Angela Dispenzieri, Leslie Amass, et al.
Pageof 6